ClinicalTrials.gg
TerminatedNCT06029595TANGOUpdated Dec 18, 2025

Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

A Phase 2 interventional study of Experimental: CHF6001 3200 μg and Placebo Comparator: CHF6001 Placebo in Uncontrolled Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Terminated at 187 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Why this study was terminated
Strategic decision by Sponsor; not due to safety reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
517
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Asthma by Chiesi Farmaceutici S.p.A. — 11 open to participants now, 11 under way, 2 of them phase 3. Asthma · Chiesi Farmaceutici S.p.A..

Enrollment
16th of 66
517 · median 97
Started
2023
with 4 others
Phase 2
25 of 81
1 open now
Registered
67th of 81
by date

Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one is the 16th largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2023, is one of 25 in phase 2, and was the 67th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

11 of the 81 studies in Asthma by Chiesi Farmaceutici S.p.A. are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Asthma by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting ß2-agonists in the target patient population. (TANGO)

03

Conditions studied

  • Uncontrolled Asthma

Browse trials for

Keywords

  • Asthma
  • PDE4 inhibitor
  • anti-inflammatory respiratory drug
  • Tanimilast
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written
  2. Male or female subjects aged ≥18 and ≤75 years
  3. A documented history of physician-diagnosed asthma for at least 1 year and with diagnosis before the age of 50 years
  4. Stable asthma therapy: a stable maintenance treatment with medium to high dose of inhaled plus long acting β2 agonists for at least 3 months prior to screening
  5. A prebronchodilator ≤80% of the predicted normal value
  6. Bronchodilator responsiveness after inhalation of salbutamol or equivalent
  7. Evidence of poorly controlled or uncontrolled asthma as based on an ACQ-7 score ≥1.5
  8. History of asthma exacerbations : at least 1 asthma exacerbation leading to hospitalisation or 2 or more asthma exacerbations within the last 12 months
  9. A cooperative attitude and ability to use inhalers and to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  1. e-Diary completion compliance \<75% during run-in
  2. History of near fatal asthma or of a past hospitalisation for asthma in intensive care unit
  3. Recent exacerbation or respiratory tract infection within 4 weeks prior to screening visit or during the run-in period
  4. Subjects using systemic medication in the 4 weeks or slow-release corticosteroids in the 12 weeks prior to randomisation
  5. Asthma requiring use of biologics
  6. Respiratory disorders other than asthma: subjects with known respiratory disorders other than asthma
  7. Subjects with a history of lung volume resection
  8. Current smokers, ex-smokers with a smoking history of ≥10 pack-years or current use of inhaled or oral cannabis products.
  9. Subjects with cancer or history of cancer
  10. Subjects with cardiovascular diseases
  11. Subjects with any abnormal and 12-lead
  12. Subjects with previous medical history, evidence of an uncontrolled intercurrent illness, or any clinically relevant abnormal findings in haematology, clinical chemistry, or urinalysis
  13. Subjects with a diagnosis of depression, generalised anxiety disorder, suicidal ideation or behaviour
  14. Patients mentally or legally incapacitated or patients accommodated in an establishment
  15. Subjects with liver diseases
  16. Drugs with hepatoxicity potential
  17. Subjects with to IMPs:
  18. Subjects with history alcohol/drug abuse
  19. Subjects with major surgery in the 3 months prior to screening visit or planned during the trial
  20. Subjects treated with non-potassium sparing diuretics, nonselective β-blocking drugs, quinidine, quinidine like anti-arrhythmic, or any medication with a prolongation potential or a history of QTc prolongation
  21. Subjects treated with monoamine oxidase inhibitors (MAOIs) and tricyclic anti-depressants
  22. Subjects receiving any therapy that could interfere with the study drugs
  23. Participation in another trial
  24. Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 2 weeks
  25. Subjects having received a vaccination within 2 weeks prior to screening or during the run-in period.
  26. For females only: pregnant or lactating women
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
517 participants (actual)

Study arms

  • Experimental
    CHF6001 - CHF6001 total daily dose 3200 μg;

    Drug: Experimental: CHF6001 3200 μg

  • Placebo comparator
    Placebo

    Drug: Placebo Comparator: CHF6001 Placebo

Interventions

  • 800 μg/actuation - 2 inhalations of CHF6001 800 μg twice daily (BID) total daily dose 3200 μg

  • DrugPlacebo Comparator: CHF6001 Placebo

    2 inhalations of CHF6001 matching placebo BID

06

What researchers measure

Primary outcomes

  1. Number of Asthma exacerbation over 52 weeks of treatment

    Number of Asthma exacerbation over 52 weeks of treatment (Asthma exacerbations defined as severe event with worsening of asthma requiring at least 3 days of SCS use with or without emergency visit or hospitalization)

    Time frame: Over 52 weeks

Secondary outcomes

  1. Time to first asthma exacerbation;

    Asthma exacerbations defined as severe event with worsening of asthma requiring at least 3 days of SCS use with or without emergency visit or hospitalization

    Time frame: Up to 52 weeks

  2. Number of asthma exacerbation and asthma worsening over 52 weeks of treatment

    Asthma exacerbations defined as severe event with worsening of asthma requiring at least 3 days of SCS use with or without emergency visit or hospitalization; Asthma worsening defined as moderate asthma exacerbation.

    Time frame: Up to 52 weeks

  3. Time to first asthma exacerbation or asthma worsening

    Asthma exacerbations defined as severe event with worsening of asthma requiring at least 3 days of SCS use with or without emergency visit or hospitalization; Asthma worsening defined as moderate asthma exacerbation.

    Time frame: Up to 52 weeks

  4. ACQ-7 responders

    ACQ-7 responders at Week 4, Week 26 and Week 52 (i.e., subjects showing improvement from baseline in ACQ-7 score of ≥0.5 units);

    Time frame: week 4, week 26 and week 52

  5. Change from baseline in ACQ-7 and ACQ-6

    Change from baseline in ACQ-7 and ACQ-6 at Week 4, Week 26 and Week 52

    Time frame: week 4, week 26 and week 52

  6. Change from baseline in Mini-AQLQ

    Change from baseline in Mini-AQLQ at Week 4, Week 26 and Week 52

    Time frame: week 4, week 26 and week 52

  7. Change from baseline in pre-dose FEV1

    Change from baseline in pre-dose FEV1 at Week 4, Week 26 and Week 52;

    Time frame: week 4, week 26 and week 52

  8. Change from baseline in pre-dose FVC

    Change from baseline in pre-dose FVC at Week4, Week 52 and Week 26;

    Time frame: Week4, Week 52 and Week 26

  9. Change from baseline (run-in period) to each inter-visit period and to the entire treatment period in pre dose morning/evening PEF;

    Time frame: Up to 52 weeks

  10. Change from baseline to each inter-visit period and to the entire treatment period in the average rescue medication use (number of puffs/day) and asthma symptoms score

    Time frame: Up to 52 weeks

  11. Change from baseline to each inter-visit period and to the entire treatment period in the percentage of rescue medication-free days, asthma symptoms-free days and asthma control days.

    Time frame: Up to 52 weeks

07

Study locations

187 sites
  • Site 032020 - Instituto Especialidades de la Salud Rosario - Clinica del Torax
    Santa Fe, La, Argentina
  • Site 032027- Centro de Medicina Respiratoria
    Argentina, Argentina
  • Site 032025 - Sala Mignaburu
    Berazategui, Argentina
  • Site 032004 - CARE - Centro de Alergia y Enfermedades Respiratorias
    Buenos Aires, Argentina
  • Site 032008 - Mautalen Salud e Investigacion
    Buenos Aires, Argentina
  • Site 032014 - Instituto de Investigaciones en Alergia y Enfermedades Respiratorias (INAER)
    Buenos Aires, Argentina
  • Site 032021 - Centro De Investigaciones Medicas Mar Del Plata
    Buenos Aires, Argentina
  • Site 032024 -CEMLO- Consultorio Medico CEMLO LOBOS
    Buenos Aires, Argentina
  • Site 032029 - Hospital de Alta Complejidad del Bicentenario de Esteban Echeverría
    Buenos Aires, Argentina
  • Site 032030 - Instituto de Diagnostico e Investigaciones Metabolicas (IDIM)
    Buenos Aires, Argentina
  • Site 032031 - Centro de Investigaciones Metabolicas (CINME) S.A.
    Buenos Aires, Argentina
  • Site 032032 - Hospital Italiano de Buenos Aires (HIBA)
    Buenos Aires, Argentina
  • Site 032003 -Fundacion Respirar (Centro Medico Dra. De Salvo) - Instituto Argentino de Investigaciones Clinicas (IAIC) S.R.L
    Ciudad de Buenos Aires, Argentina
  • Site 032026 - IAAER-Instituto de Asma, Alergia y Enfermedades Respiratorias
    Corrientes, Argentina
  • Site 032005 - National University of Cordoba - Rusculleda Foundation - Instituto DAMIC
    Córdoba, Argentina
  • Site 032010 - Centro Platense en Investigaciones Respiratorias - CEPIR
    La Plata, Argentina
  • Site 032013 - Centro de Investigacion Medico Lanus-CIMEL CHAHIN CHAHIN S.A
    Lanus, Argentina
  • Site 032006 -Institute Fundacion Enfisema - Instituto Ave Pulmo; Hospital Privado de Comunidad (HPC)
    Mar del Plata, Argentina
  • Site 032002 -Consultorios Medicos Dr Isaac Scherbovsky - Fundacion Scherbovsky
    Mendoza, Argentina
  • Site 032009 - Centro Medico INSARES
    Mendoza, Argentina
  • Site 032023 - Respira Salud Clinica Integral
    Mendoza, Argentina
  • Site 032011 - Centro Privado de Medicina Respiratoria de Parana - CPMR
    Paraná, Argentina
  • Site 032007 - Instituto Especialidades de la Salud Rosario - Clinica del Torax
    Rosario, Argentina
  • Site 032016 - Instituto Medico de la Fundacion Estudios Clinicos
    Rosario, Argentina
  • Site 032019 - Servicio de Investigacion de Patologias Alergicas del Instituto ABC - Rosario
    Rosario, Argentina
  • Site 032001 - Instituto de Enfermedades Respiratorias e Investigacion Medica- IERIM
    San Juan Bautista, Argentina
  • Site 032015 - Fundacion de Estudios Clinicos de Consultorio Integrados Rosario
    San Miguel de Tucumán, Argentina
  • Site 032018 - Instituto de Investigaciones en Patologias Respiratorias
    San Miguel de Tucumán, Argentina
  • Site 032022 - Clinica Mayo de Urgencias Medicas Cruz Blanca SRL
    San Miguel de Tucumán, Argentina
  • Site 032012 - Instituto Del Buen Aire
    Santa Fe, Argentina
  • Site 032028 - Instituto De Investigaciones Clnicas De Rosario
    Santa Fe, Argentina
  • Site 032017 - Centro Medico de Enfermedades Respiratorias (CEMER)
    Vicente López, Argentina
  • Site 100012 - Medical Center Asklepii OOD
    Dupnitsa, Bulgaria
  • Site 100005 _MHAT Dr. Tota Venkova AD
    Gabrovo, Bulgaria
  • Site 100011 - Medical Center Pulmo-2018 EOOD
    Haskovo, Bulgaria
  • Site 100022 - MHAT Dr. Atanas Dafovski AD
    Kardzhali, Bulgaria
  • Site 100021 - MC Zdrave 1
    Kozloduy, Bulgaria
  • Site 100003 - """DCC 1 - Pernik"" EOOD"
    Pernik, Bulgaria
  • Site 100010 - Medical Center FAMA
    Plovdiv, Bulgaria
  • Site 100017 - MHAT Sveti Panteleymon EOOD
    Plovdiv, Bulgaria
  • Site 100025 - Dr. Filip Shterev - Individual ambulatory practice for specialized medical care
    Plovdiv, Bulgaria
  • Site 100024 - Medical center Respiro
    Razgrad, Bulgaria
  • Site 100006 _ Ambulatory For Specialized Outpatient Medical Care - Individual Practice - Dr. Nikolay Evgeniev Ruse Ltd
    Rousse, Bulgaria
  • Site 100014 -SBALPFZ - Ruse EOOD
    Rousse, Bulgaria
  • Site 100029 - DCC 1 Sevlievo
    Sevlievo, Bulgaria
  • Site 100016 - MHAT Shumen AD
    Shumen, Bulgaria
  • Site 100004 - MHAT Dr. Ivan Seliminski AD
    Sliven, Bulgaria
  • Site 100028 - Smolyan Clinical Research Center
    Smolyan, Bulgaria
  • Site 100001- 5th MHAT - Sofia EAD
    Sofia, Bulgaria
  • Site 100002 _MHAT St. Ekaterina Dimitrovgrad
    Sofia, Bulgaria
  • Site 100008 _Diagnostic Consultative Center Convex Ltd
    Sofia, Bulgaria
  • Site 100013 - MHAT Lyulin EAD
    Sofia, Bulgaria
  • Site 100015 - Hospital for Pneumatic Physiatric Diseases - Sofia
    Sofia, Bulgaria
  • Site 100018 - Medical Center Excelsior Ltd
    Sofia, Bulgaria
  • Site 100019 - Aleksandrovska University Hospital
    Sofia, Bulgaria
  • Site 100020 -Medical Centre N. I. Pirogov EOOD
    Sofia, Bulgaria
  • Site 100023 - University First Multiprofile Hospital for Active treatment-Sofia EAD
    Sofia, Bulgaria
  • Site 100030 - Medical Center Hera EOOD
    Sofia, Bulgaria
  • Site 100009 - Medical Center Kissiovi
    Varna, Bulgaria
  • Site 100027 - Medical Center Research Expert
    Varna, Bulgaria
  • Site 100007 _SHATPPD Vratsa
    Vratsa, Bulgaria
  • Site 203001 -MUDr. I. Cierna Peterova s.r.o.
    Brandýs nad Labem, Czechia
  • Site 203008 - Fakultni nemocnice Brno
    Brno, Czechia
  • Site 203002 - MediTrial s.r.o.
    Jindřichův Hradec, Czechia
  • Site 203009 - Alergologie Nemcova s.r.o
    Lískovec, Czechia
  • 203004 -Nemocnice Mesice
    Měšice, Czechia
  • Site 203006 - Nemocnice Znojmo
    Ostrava, Czechia
  • Site 203010 - DAWON Spol. s r.o. - Pneumologicka Ambulance
    Prague, Czechia
  • Site 203011 -Ordinace chorob plicnich s.r.o.
    Prague, Czechia
  • Site 203003 - Plicni Stredisko Teplice, s.r.o.
    Teplice, Czechia
  • Site 203005 - Ambulance Pneumologie a Ftizeologie
    Varnsdorf, Czechia
  • Site 268001 - Chapidze Emergency Cardiology Center
    Tbilisi, Georgia
  • Site 268002 - JSC German Hospital
    Tbilisi, Georgia
  • Site 268003 - French Joint Hepatology Clinic Hepa
    Tbilisi, Georgia
  • Site 268004 - LTD Helsicore
    Tbilisi, Georgia
  • Site 268005 - LLC Medi Club Georgia
    Tbilisi, Georgia
  • Site 268006 - The Firsts University Clinic of Tbilisi State Medical University
    Tbilisi, Georgia
  • Site 268007 - TSMU & Ingorokva High Medical Technologies University Clinic
    Tbilisi, Georgia
  • Site 276004 - RCMS
    Berlin, Germany
  • Site 276012 - Institut fuer Allergie- und Asthmaforschung Berlin
    Berlin, Germany
  • Site 276013 - MECS Research
    Berlin, Germany
  • Site 276010 - Office of Dr. Thomas Ginko, MD
    Bonn, Germany
  • Site 276014 - MECS Cottbus GmbH
    Cottbus, Germany
  • Site 276019 - Praxis Dr. Eckhardt
    Delitzsch, Germany
  • Site 276007 - IKF Institut fuer klinische Forschung Frankfurt
    Frankfurt am Main, Germany
  • Site 276008 - Office of Dr. med. Claus Keller MD
    Frankfurt am Main, Germany
  • Site 276003 - ME Clinical Respiratory Research Hamburg
    Hamburg, Germany
  • Site 276015 - Velocity Clinical Research Hamburg GmbH
    Hamburg, Germany
  • Site 276002 - Pneumologicum im Suedstadtforum - Hannover
    Hanover, Germany
  • Site 276009 - Velocity Clinical Research Leipzig GmbH
    Leipzig, Germany
  • Site 276011 - POIS Sachsen GmbH
    Leipzig, Germany
  • Site 276020 - BAG Prof. Gerhard Hoheisel/Dr. Andreas Bonitz Praxis für Pneumologie und Allergologie-Studienzentrum
    Leipzig, Germany
  • Site 276006 - IKF Pneumologie Mainz, Helix Medical Excellence Center Mainz
    Mainz, Germany
  • Site 276001 - Studienzentrum Muenchen-West; Gemeinschaftspraxis fuer Lungen- und Bronchialheilkunde Prof. Dr. med. Rainald Fischer und Dr. med. Michael Baborka
    München, Germany
  • Site 276021 - Pneumologische Gemeinschaftspraxis Rheine
    Rheine, Germany
  • Site 276022 - Universitaetsmedizin Rostock
    Rostock, Germany
  • Site 276016 - Praxisgemeinschaft in Saalfeld - HNO
    Saalfeld, Germany
  • Site 276018 - Siteworks Prufzentrum Schleswig-RespiRatio
    Schleswig, Germany
  • Site 276005 - Lungenzentrum Ruhr - Praxis fuer Lungenheilkunde
    Witten, Germany
  • Site 348006 - Bajcsy-Zsilinszky Hospital
    Budapest, Hungary

Showing the first 100 of 187 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2025, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Sep 8, 2023
StartActual
Nov 26, 2023
Primary completionActual
Dec 9, 2025
CompletionActual
Dec 9, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06029595
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Nov 26, 2023
Primary completion
Dec 9, 2025
Completion
Dec 9, 2025
Last update
Dec 18, 2025

Study contacts

Johann Christian VIRCHOW, Prof
principal investigator · Universitätsmedizin Rostock

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanimilast

Start the discussion